The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of durvalumab (MEDI4736) in combination with a CSF-1R inhibitor (SNDX-6352) following chemotherapy or radio-embolization for patients with intrahepatic cholangiocarcinoma.
 
Marina Baretti
Consulting or Advisory Role - Exelixis
 
Yingjun Ding
No Relationships to Disclose
 
Madalena Brancati
No Relationships to Disclose
 
Rose Parkinson
No Relationships to Disclose
 
Sheila Linden
No Relationships to Disclose
 
Kelvin Hong
Consulting or Advisory Role - Boston Scientific; BTG
Research Funding - BTG
 
Robert Liddell
No Relationships to Disclose
 
Lei Zheng
Consulting or Advisory Role - Akrevia Therapeutics; Alphamab; Amberstone; Ambrx; BioArdis; Biosion; Natera; Novagenesis; NovaRock; QED Therapeutics; Snow Lake Capital; Tempus
Research Funding - ABMETA Therapeutics; Amgen; AstraZeneca; Bristol-Myers Squibb; Halozyme; Inxmed; iTEOS Therapeutics; Merck